Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Abdullatif Al Khedr, Pei‐Ran Ho et al.|The Lancet Neurology|2018Cited by 345
Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer AcetateCatherine M. Edgar, Peter Green, Donald Brunet et al.|Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques|2004Cited by 64